Abstract
Prediabetes and diabetes mellitus (DM) are established risk factors for newly occurred heart failure (HF) with reduced and preserved ejection fraction. Natriuretic peptides (NPs) were found to be useful tool for CV risk stratification among patients with prediabetes and type 2 DM (T2DM) regardless of HF phenotype. Previous clinical studies have shown that elevated levels of NPs predicted all-cause mortality and CV mortality, risk of HF occurrence and progression, as well as a risk readmission due to HF. The discriminative potency of NPs for CV death and HF-related clinical events in prediabetes and T2DM populations has not been demonstrated beyond traditional CV risk factors. The aim of the review is to accumulate knowledge regarding predictive value of circulating NPs depending on presentation of prediabetes and established T2DM. It has been found that HFrEF or HFpEF in T2DM patients may require modification of NP cutoff points to primary diagnose HF and determine HF-related risks. There are several controversies between clinical outcomes and dynamic of circulating levels of NPs in diabetics treated with glucagon-like peptide-1 agonists and sodium-glucose cotransporter-2 inhibitors that require to be elucidated in large clinical studies in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
